Benefits of Erlotinib Maintenance in NSCLC: SATURN Results Published

Nick Mulcahy

May 20, 2010

May 20, 2010 — Results from the phase 3 Sequential Tarceva in Unresectable NSCLC (SATURN) trial are now published online in The Lancet Oncology.

The results show that, compared with placebo, erlotinib (Tarceva, Genentech/OSI Pharmaceuticals) maintenance therapy significantly improves progression-free survival (hazard ratio [HR], 0.71; median, 12.3 vs 11.1 weeks) and overall survival (HR, 0.81; median, 12.0 vs 11.0 months) in patients with advanced nonsmall-cell lung cancer (NSCLC).

The data were first presented at the 2009 World Conference on Lung Cancer and reported by Medscape Oncology at the time.

The most dramatic outcomes with erlotinib were seen in a small subset of patients in the trial — those with an epidermal growth-factor receptor (EGFR) mutation — but these patients accounted for only 22 of the 438 (5%) erlotinib-treated patients.

"Erlotinib was associated with an unprecedented hazard ratio of 0.10 (P < .0001) for patients with an EGFR mutation," said Thomas E. Stinchcombe, MD, and Suresh S. Ramalingam, MD, in an editorial that accompanies the study results.

However, this unprecedented result for progression-free survival did not translate into a statistically significant improvement in overall survival, probably because most of the patients on placebo with an EGFR mutation received treatment with erlotinib upon progression, note Dr. Stinchcombe, from the University of North Carolina at Chapel Hill, and Dr. Ramalingam, from Emory University in Atlanta, Georgia.

This crossover effect on overall survival does not diminish the impressiveness of the improvement in progression-free survival in patients with an EGFR mutation — even if it is a small, limited group, suggest the editorialists.

"It has become clear that robust responses and prolonged [progression-free survival] outcomes with EGFR tyrosine-kinase inhibitors (TKIs) are limited to patients with an EGFR mutation," they summarize.

EGFR TKIs, which include gefitinib (Iressa, AstraZeneca), are well suited for maintenance therapy in this setting, the editorialists point out.

"Their proven efficacy, ease of administration, and favorable tolerability profile make them ideal for maintenance therapy," they write, adding that the quality-of-life indices in SATURN did not show any "significant differences" between the treatment and placebo groups.

In SATURN, the most common grade 3 or higher adverse events were rash (9% in the erlotinib group vs 0% in the placebo group) and diarrhea (2% vs 0%), report the study authors, led by Federico Cappuzzo, MD, from Ospedale Civile di Livorno in Italy.

Pemetrexed or Erlotinib for Patients With Wild-Type EGFR?

Maintenance therapy for NSCLC is defined as the use of an effective agent in the absence of disease progression following platinum-based combination chemotherapy, the editorialists explain.

An outstanding question for clinicians is whether or not erlotinib is the best choice for maintenance therapy in patients with wild-type EGFR.

Patients with wild-type EGFR accounted for 45% and 42% of the treatment and placebo groups, respectively, in the 889-patient SATURN trial.

But the trial results indicate that erlotinib was not highly effective in NSCLC patients with wild-type EGFR.

"The benefit of maintenance erlotinib compared with placebo in terms of progression-free survival and overall survival was modest for such patients," write Drs. Stinchcombe and Ramalingam, referring to the wild-type patients.

Pemetrexed is a better choice for maintenance therapy in patients with wild-type EGFR, suggest the editorialists.

Pemetrexed is "likely to be the preferred agent in patients with nonsquamous histology, based on the improvement in median survival of 5 months seen with pemetrexed compared with placebo," they opine, suggesting that patients with squamous cell carcinomas are unlikely to have the mutation.

Both pemetrexed and erlotinib are approved by the US Food and Drug Administration as maintenance therapies for patients with advanced NSCLC.

The editorialists remind clinicians that they should remain mindful that maintenance therapy is not for all patients with advanced NSCLC who have stable disease after chemotherapy.

"The decision to administer maintenance therapy should take into consideration the disease burden, extent of symptoms, the toxicities associated with first-line therapy, and patient preferences. While maintenance therapy might be appropriate for some patients, it might be less preferable for others," write Dr. Stinchcombe and Dr. Ramalingam.

The SATURN trial was funded by F. Hoffman-La Roche. Dr. Stinchcombe reports being on the speakers' bureau of Lilly and Genentech. Dr. Ramalingam reports working as a consultant for Genentech, Imclone, Syndax, Astellas, Amgen, and GlaxoSmithKline. Dr. Cappuzzo reports receiving honoraria from Roche, Eli-Lilly, AstraZeneca, and Boehringer; and receiving payment for development of educational presentations, including service on speakers' bureaus, from Roche, Eli-Lilly, AstraZeneca, and Boehringer.

Lancet Oncol. Published online May 20, 2010.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.